Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $563
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.
Share
Why It Matters
An analyst who watches Vertex thinks the company is worth more money now. That suggests Vertex is doing things right, but the analyst still thinks waiting is wise.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.